![Apomorphine subcutaneous infusion reduces dopaminergic dosage whilst maintaining motor benefits in Parkinson's disease: A prospective analysis of Thai Apomorphine Registry - MDS Abstracts Apomorphine subcutaneous infusion reduces dopaminergic dosage whilst maintaining motor benefits in Parkinson's disease: A prospective analysis of Thai Apomorphine Registry - MDS Abstracts](http://www.mdsabstracts.org/wp-content/uploads/2020/09/0417_0603_001621_003.png)
Apomorphine subcutaneous infusion reduces dopaminergic dosage whilst maintaining motor benefits in Parkinson's disease: A prospective analysis of Thai Apomorphine Registry - MDS Abstracts
![A case series of rapid titration of subcutaneous apomorphine in Parkinson's disease | British Journal of Neuroscience Nursing A case series of rapid titration of subcutaneous apomorphine in Parkinson's disease | British Journal of Neuroscience Nursing](https://www.magonlinelibrary.com/cms/10.12968/bjnn.2016.12.2.70/asset/images/medium/bjnn.2016.12.2.70_t03.jpg)
A case series of rapid titration of subcutaneous apomorphine in Parkinson's disease | British Journal of Neuroscience Nursing
![FDA Approves Apomorphine Sublingual Film for Treatment of OFF Periods in Parkinson Disease - Practical Neurology FDA Approves Apomorphine Sublingual Film for Treatment of OFF Periods in Parkinson Disease - Practical Neurology](https://core4.bmctoday.net/storage/images/MovementDisordersTable1_1590101721.jpg)
FDA Approves Apomorphine Sublingual Film for Treatment of OFF Periods in Parkinson Disease - Practical Neurology
![Sunovion Pharmaceuticals Inc. - Sunovion Announces U.S. FDA Approval of KYNMOBI™ (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson's Disease OFF Episodes Sunovion Pharmaceuticals Inc. - Sunovion Announces U.S. FDA Approval of KYNMOBI™ (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson's Disease OFF Episodes](https://s23.q4cdn.com/866595044/files/doc_multimedia/1._KYNMOBI_Logo_highres.jpg)
Sunovion Pharmaceuticals Inc. - Sunovion Announces U.S. FDA Approval of KYNMOBI™ (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson's Disease OFF Episodes
![Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: Preliminary Results from a Phase III Study - MDS Abstracts Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: Preliminary Results from a Phase III Study - MDS Abstracts](https://www.mdsabstracts.org/wp-content/uploads/2017/05/0037-001034_001.jpg)
Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: Preliminary Results from a Phase III Study - MDS Abstracts
![Apomorphine subcutaneous infusion reduces dopaminergic dosage whilst maintaining motor benefits in Parkinson's disease: A prospective analysis of Thai Apomorphine Registry - MDS Abstracts Apomorphine subcutaneous infusion reduces dopaminergic dosage whilst maintaining motor benefits in Parkinson's disease: A prospective analysis of Thai Apomorphine Registry - MDS Abstracts](http://www.mdsabstracts.org/wp-content/uploads/2020/09/0417_0603_001621_006.png)
Apomorphine subcutaneous infusion reduces dopaminergic dosage whilst maintaining motor benefits in Parkinson's disease: A prospective analysis of Thai Apomorphine Registry - MDS Abstracts
![Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial - The Lancet Neurology Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial - The Lancet Neurology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/5a5b4ae1-081c-4838-87c8-d173ef2e247b/gr1_lrg.jpg)
Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial - The Lancet Neurology
![PDF) Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease PDF) Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease](https://www.researchgate.net/publication/321628710/figure/tbl1/AS:863948807102465@1582992855321/Currently-marketed-apomorphine-formulations_Q320.jpg)
PDF) Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease
![Sunovion Announces U.S. FDA Approval of KYNMOBI™ (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson's Disease OFF Episodes | Business Wire Sunovion Announces U.S. FDA Approval of KYNMOBI™ (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson's Disease OFF Episodes | Business Wire](https://mms.businesswire.com/media/20200521005786/en/793337/5/PD_OFF-Episodes-Infographic.jpg)
Sunovion Announces U.S. FDA Approval of KYNMOBI™ (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson's Disease OFF Episodes | Business Wire
![Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson's Disease and “OFF” Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study | SpringerLink Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson's Disease and “OFF” Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40120-021-00251-6/MediaObjects/40120_2021_251_Fig1_HTML.png)